Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Salute | Prodotti farmaceutici | 707,03 Bln ARS | 83,7x | 1,26 | 15.850 ARS | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson & Johnson | Buenos Aires | Salute | Prodotti farmaceutici | 359,18 Bln ARS | 24x | -1,28 | 815 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 355,42 Bln ARS | 23,7x | 1.300 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Johnson & Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 355,42 Bln ARS | 23,7x | -0,44 | 11.175 ARS | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abbvie | Buenos Aires | Salute | Prodotti farmaceutici | 317,54 Bln ARS | 61,5x | -2,81 | 20.450 ARS | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck & Co DRC | Buenos Aires | Salute | Prodotti farmaceutici | 254,35 Bln ARS | 20,6x | 0,13 | 22.850 ARS | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca PLC | Buenos Aires | Salute | Prodotti farmaceutici | 204,82 Bln ARS | 30,8x | 3,22 | 37.950 ARS | 1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis DRC | Buenos Aires | Salute | Prodotti farmaceutici | 198,68 Bln ARS | 11,2x | 0,13 | 28.275 ARS | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pfizer DRC | Buenos Aires | Salute | Prodotti farmaceutici | 152,71 Bln ARS | 35,1x | -0,57 | 7.660 ARS | 3,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Amgen AR | Buenos Aires | Salute | Prodotti farmaceutici | 145,83 Bln ARS | 33,8x | -0,77 | 10.300 ARS | 3,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Salute | Prodotti farmaceutici | 118,28 Bln ARS | -15,9x | 0,08 | 21.875 ARS | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gilead Sciences | Buenos Aires | Salute | Prodotti farmaceutici | 118,10 Bln ARS | 918,3x | -9,28 | 26.775 ARS | 2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
GSK plc DRC | Buenos Aires | Salute | Prodotti farmaceutici | 69,42 Bln ARS | 21,5x | -0,37 | 9.860 ARS | 2,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cardinal Health | Buenos Aires | Salute | Prodotti farmaceutici | 29,16 Bln ARS | 22,4x | 0,04 | 45.675 ARS | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Biogen AR | Buenos Aires | Salute | Prodotti farmaceutici | 21,83 Bln ARS | 13,1x | 1,35 | 13.075 ARS | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Laboratorios Richmond | Buenos Aires | Salute | Prodotti farmaceutici | 143,33 Mrd ARS | 8,4x | 0,03 | 1.755 ARS | 3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Inst rosembusc | Buenos Aires | Salute | Prodotti farmaceutici | 5,11 Mrd ARS | 5,1x | 0,02 | 120 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |